{"title":"Basic science: (JUNE 2008)","authors":"R. Sutherland","doi":"10.1017/S1470903108008432","DOIUrl":"https://doi.org/10.1017/S1470903108008432","url":null,"abstract":"1. Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 2008; 112: 2352–2358. 2. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68: 4026–4030. 3. Bartella V, Cascio S, Fiorio E, Auriemma A, Russo A, Surmacz E. Insulin-dependent leptin expression in breast cancer cells. Cancer Res 2008; 68: 4919–4927. 4. Botlagunta M, Vesuna F, Mironchik Y, Raman A, Lisok A, Winnard P, Mukadam S, Van Diest P, Chen JH, Farabaugh P, Patel AH, Raman V. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene 2008; 27: 3912–3922. 5. Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, Bajetta E, Celio L, Greco M, Fabbri A, Pierotti MA, Daidone MG. Patterns and changes in gene expression following neoadjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr-Rel Cancer 2008; 15: 439–449. 6. D’Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Farrugia DJ, Schroeder MA, Allen C, Stivala F, Galanis E, Salisbury JL. Impaired p53 function leads to centrosome amplification, acquired ER a phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene 2008; 27: 3901–3911. 7. Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, VanVeldhuizen PJ, Banerjee SK. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 2008; 68: 4580–4587. 8. Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK, Song J, Mershon J, Barrett-Connor E. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 2008; 100: 854–861. 9. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008; 30: 701–711. 10. Kijima I, Ye J, Glackin C, Chen S. CCAAT/ enhancer binding protein d up-regulates aromatase promoters I.3/II in breast cancer epithelial cells. Cancer Res 2008; 68: 4455–4464. 11. Kojima Y, Akimoto K, Nagashima Y, Ishiguro H, Shirai S, Chishima T, Ichikawa Y, Ishikawa T, Sasaki T, Kubota Y, Inayama Y, Aoki I, Ohno S, Shimada H. The overexpression and altered localization of the atypical protein kinase C l/i in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 2008; 39: 824–831. 12. Lee JY, Jang KS, Shin DH, Oh MY, Kim HJ, Kim Y, Kong G. Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res 2008; 68: 4201–4209. 13. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, Carney W. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxife","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Review of: The Ets transcription factor Elf5 specifies mammary alveolar cell fate","authors":"J. Stingl","doi":"10.1017/S1470903108008419","DOIUrl":"https://doi.org/10.1017/S1470903108008419","url":null,"abstract":"Citation of the original article: S. R. Oakes, M. J. Naylor, M. L. Asselin-Labat, K. D. Blazek, M. Gardiner-Garden, H. N. Hilton, M. Kazlauskas, M. A. Pritchard, L. A. Chodosh, P. L. Pfeffer, G. J. Lindeman, J. E. Visvader, C. J. Ormandy. Genes Dev 2008; 22 (5): 581–586. Abstract of the original article: Hormonal cues regulate mammary development, but the consequent transcriptional changes and cell fate decisions are largely undefined. We show that knockout of the prolactin-regulated Ets transcription factor Elf5 prevented formation of the secretory epithelium during pregnancy. Conversely, overexpression of Elf5 in an inducible transgenic model caused alveolar differentiation and milk secretion in virgin mice, disrupting ductal morphogenesis. CD61+ luminal progenitor cells accumulated in Elf5-deficient mammary glands and were diminished in glands with Elf5 overexpression. Thus Elf5 specifies the differentiation of CD61+ progenitors to establish the secretory alveolar lineage during pregnancy, providing a link between prolactin, transcriptional events, and alveolar development.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008419","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Strategies to enhance radiosensitivity in breast cancer","authors":"S. Formenti","doi":"10.1017/S1470903108008183","DOIUrl":"https://doi.org/10.1017/S1470903108008183","url":null,"abstract":"Radiotherapy is an important component in the treatment of breast cancer. However, the individual tumor response to radiation is variable, reflecting both the intrinsic properties of the tumor and its microenvironment as well as the different, inherited sensitivity of the patient’s normal tissue when exposed to the effect of ionizing radiation. These differences have inspired research to discover the underlying signal transduction pathways and to understand when they pertain to the tumor, the host or both. In fact, understanding the mechanisms underlying radiosensitivity of breast cancer not only does it permit to design more effective radiation treatments, but it sheds light on the complexities of tumor-host interactions in this disease.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Basic science: (May 2008)","authors":"R. Sutherland","doi":"10.1017/S1470903108008420","DOIUrl":"https://doi.org/10.1017/S1470903108008420","url":null,"abstract":"1. Al-Azawi D, Mc Ilroy M, Kelly G, Redmond AM, Bane FT, Cocchiglia S, Hill ADK, Young LS. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008; 27: 3021–3031. 2. Barabutis N, Schally AV. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 2008; 98: 1790–1796. 3. Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE. The Ret receptor tyrosine kinase pathway functionally interacts with the ER a pathway in breast cancer. Cancer Res 2008; 68: 3743–3751. 4. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MBK, Reis JS, Ellis IO. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008; 109: 325–335. 5. Euhus DM, Bu DW, Milchgrub S, Xie XJ, Bian A, Leitch AM, Lewis CM. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 1051–1059. 6. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008; 68: 3523–3531. 7. Fereshteh MP, Tilli MT, Kim SE, Xu JM, O’Malley BW, Wellstein A, Furth PA, Riegel AT. The nuclear receptor coactivator amplified in breast cancer-1 is required for neu (ErbB2/ HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 2008; 68: 3697–3706. 8. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen HY, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518–527. 9. Frech MS, Torre KM, Robinson GW, Furth PA. Loss of cyclin D1 in concert with deregulated estrogen receptor a expression induces DNA damage response activation and interrupts mammary gland morphogenesis. Oncogene 2008; 27: 3186–3193. 10. Golipour A, Myers D, Seagroves T, Murphy D, Evan GI, Donoghue DJ, Moorehead RA, Porter LA. The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Res 2008; 68: 3591–3600. 11. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ. Estrogen receptor b increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2008; 109: 241–250. 12. Hollingshead BD, Beischlag TV, DiNatale BC, Ramadoss P, Perdew GH. Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. Cancer Res 2008; 68: 3609–3617. 13. Howarth KD, Blood KA, Ng BL, Beavis JC, Chua Y, Cooke SL, Raby S, Ichimura K, Collins VP, Carter NP, Edwards PAW. Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that brea","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Basic science: (April 2008)","authors":"R. Sutherland","doi":"10.1017/S1470903108008365","DOIUrl":"https://doi.org/10.1017/S1470903108008365","url":null,"abstract":"1. Ahmad R, Raina D, Meyer C, Kufe D. Triterpenoid CDDO-methyl ester inhibits the janus-activated kinase-1 (JAK1)Signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 2008; 68: 2920–2926. 2. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Passini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PDP, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008; 98: 1457–1466. 3. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kampjarvi K, Nevanlinna H, Simard J, Beesley J, Chen XQ, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Bium JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LHM, Greene MH, Rennert G, Leibkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benitez J, Hamann U, Hogervorst FBL, Manders P, Ligtenberg MJL, van den Ouweland AMW, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Paillerets BBD, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D, Easton DF. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82: 937–948. 4. Bennett HL, Brummer T, Jeanes A, Yap AS, Daly RJ. Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis. Oncogene 2008; 27: 2693–2704. 5. Caldon CE, Swarbrick A, Lee CSL, Sutherland RL, Musgrove EA. The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 2008; 68: 3026–3036. 6. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong WJ. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68: 2592–2598. 7. Crawford NPS, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, Lee MP, Ozato K, Hunter KW. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA 2008; 105: 6380–6385. 8. Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, Andre J, Bobin JY. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008365","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Primary cerebral metastasis in bilateral breast cancer","authors":"B. Ataseven, A. Staunton, W. Eiermann","doi":"10.1017/S1470903108007839","DOIUrl":"https://doi.org/10.1017/S1470903108007839","url":null,"abstract":"We present the case of a 53-year-old patient complaining of a left-sided breast lump, which she had first noticed 2 years back following trauma to the breast caused by a fall. She had consulted a doctor about the lump 3 days prior to attending our department. The patient denied any further symptoms or signs. Clinically, she presented with the following findings (Fig. 1): a red, fist-sized, non-ulcerating exophytic lump protruding from the upper quadrant of the left breast. The remaining breast tissue consisted of what felt like a tumor conglomerate. The right breast was characterized by very suspicious, irregular thickened tissue extending for several centimeters. There were pathological lymph nodes palpable in both axillae. Ultrasound examination revealed in the left breast next to the 8–9 cm clinically exophytic tumor, a second suspicious area measuring 8 mm at in the area between the left upper and lower inner quadrants approximately at 8 cm distance from the nipple. On the right side, ultrasound revealed a suspicious, inhomogenous area. There were bilateral enlarged supra-clavicular lymph nodes (Fig. 2), which were clinically metastatic. The patient refused mammography. Stance biopsy revealed a right-sided invasive receptor-positive lobular carcinoma (her2 negative) and a left-sided invasive receptor negative ductal carcinoma (her2 negative). Treatment and outcome","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108007839","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Basic science: (March 2008)","authors":"R. Sutherland","doi":"10.1017/S1470903108008353","DOIUrl":"https://doi.org/10.1017/S1470903108008353","url":null,"abstract":"1. Arendt LM, Schuler LA. Transgenic models to study actions of prolactin in mammary neoplasia. J Mammary Gland Biol Neoplasia 2008; 13: 29–40. 2. Bai T, Luoh SW. GRB-7 facilitates HER-2/ Neu-mediated signal transduction and tumor formation. Carcinogenesis 2008; 29: 473–479. 3. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008; 122: 1324–1332. 4. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008; 14: 1340–1348. 5. Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 2008; 6: 435–445. 6. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008; 14: 1744–1752. 7. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype. Clin Cancer Res 2008; 14: 1368–1376. 8. Cortesio CL, Chan KT, Perrin BJ, Burton NO, Zhang S, Zhang ZY, Huttenlocher A. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J Cell Biol 2008; 180: 957–971. 9. Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Trilleux I, Scoazec JY, Bachelot T, Bernet A, Mehlen P. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA 2008; 105: 4850–4855. 10. Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, Silva ID, Ashworth A, Houlston R, Peto J. Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 702–705. 11. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histologyand hormone receptordefined invasive breast cancer. J Clin Oncol 2008; 26: 1260–1268. 12. Frank B, Wiestler M, Kropp S, Hemminki K, Spurdle AB, Sutter C, Wappenschmidt B, Chen XQ, Beesley J, Hopper JL, Meindl A, Kiechle M, Slanger T, Bugert P, Schmutzler RK, Bartram CR, Flesch-Janys D, Mutschelknauss E, Ashton K, Salazar R, Webb E, Hamann U, Brauch H, Justenhoven C, Ko YD, Bruning T, Silva IDS, Johnson N, Pharoah PPD, Dunning AM, Pooley KA, Chang-Claude J, Easton DF, Peto J, Houlston R, Chenevix-Trench G, Fletcher O, Burwinkel B. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst 2008; 100: 437–442. 13. Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garbe","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008353","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hypofractionated whole breast irradiation","authors":"J. Yarnold","doi":"10.1017/S1470903108007694","DOIUrl":"https://doi.org/10.1017/S1470903108007694","url":null,"abstract":"The international standard regimen of radiotherapy for women with early breast cancer following mastectomy or local tumour excision involves the delivery of daily doses (fractions) of 2.0 Gy to a total dose of 50 Gy. Recent randomised clinical trials suggest that there is most unlikely to be any disadvantages in terms of local tumour control or late adverse effects, and obvious advantages in terms of convenience, for schedules treating to a lower total dose using a smaller number of larger fractions. Fifteen or 16 fractions of 2.67 Gy are being adopted in some countries, and future research will test the limits of this approach, termed accelerated hypofractionation.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108007694","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Basic science: (February 2008)","authors":"R. Sutherland","doi":"10.1017/S1470903108008304","DOIUrl":"https://doi.org/10.1017/S1470903108008304","url":null,"abstract":"1. Arnes JB, Collett K, Akslen LA. Lesson of the month – independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology 2008; 52: 370–380. 2. Averous J, Fonseca BD, Proud CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 2008; 27: 1106–1113. 3. Bergarnaschi A, Tagliabue E, Sorlie T, Naurne B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Menard S, Borresen-Dale AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214: 357–367. 4. Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci USA 2008; 105: 3527–3532. 5. Fritah A, Saucier C, De Wever O, Bracke M, Bieche I, Lidereau R, Gespach C, Drouot S, Redeuilh G, Sabbah M. Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 2008; 28: 1114–1123. 6. Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, Baron JA, Egan KM, Willett WC. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 379–386. 7. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt ANJ, Crook T, Lord CJ, Ashworth A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008; 13: 91–104. 8. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141–152. 9. Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 2008; 27: 1472–1477. 10. Levy N, Tatomer D, Herber CB, Zhao XY, Tang H, Sargeant T, Ball LJ, Summers J, Speed TP, Leitman DC. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol 2008; 22: 287–303. 11. Liu HL, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Therap 2008; 7: 263–270. 12. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008; 105: 1680–1685. 13. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, Licht JD, Ishii S. ATF-2 controls transcription of Maspin and GADD45 a genes independently from p53 to suppress mammary tumors. Oncogene 2008; 27: 1045–1054. 14. Meijer D, Jansen M, Look M, Ru","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008304","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
